The European Commission has granted marketing authorisation for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use.
As reported in Veterinary Times (VT47.09), the authorisation removes the final hurdle that now allows UK vets access to a powerful new weapon in the treatment of dogs suffering atopic dermatitis.
Cytopoint from Zoetis is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing three kilograms or more.
Cytopoint targets and neutralises canine interleukin-31 (cIL-31), a key protein involved in triggering itch in dogs.
Administered by injection once monthly, it provides fast, long-lasting relief of itching – the hallmark sign of the allergic skin condition atopic dermatitis in dogs – and the inflammation and lesions it causes.
Available from July
The manufacturers state the product helps improve the long-term health and quality of life for dogs suffering from atopic dermatitis and eases the related frustration and concern of their owners.
Atopic dermatitis is one of the most problematic skin condition in dogs and is estimated to affect 7-10% of the UK’s 8.5m dog population (2015 figures).
Cytopoint will be available to veterinary dermatology specialists through an early experience programme at the beginning of July, and to veterinarians in European Union countries in the autumn.
- For further information, visit the European Medicines Authority’s website.